424
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Anti-trypanosomal activity of (8-hydroxymethylen)-trieicosanyl acetate against infective forms of Trypanosoma cruzi

, , , &
Pages 666-671 | Received 07 Sep 2008, Accepted 16 Apr 2009, Published online: 30 Apr 2010

Figures & data

Figure 1. Parasitemic curves of BALB/c mice infected with 50,000 trypomastigotes of the H4 strain of T. cruzi and treated by the oral route with (8-hydroxymethylen)-trieicosanyl acetate at doses of 2.11, 8.4, and 33.6 µg/g and allopurinol (8.5 µg/g) for 28 days. Values represent means + SD (*p<0.05).

Figure 1.  Parasitemic curves of BALB/c mice infected with 50,000 trypomastigotes of the H4 strain of T. cruzi and treated by the oral route with (8-hydroxymethylen)-trieicosanyl acetate at doses of 2.11, 8.4, and 33.6 µg/g and allopurinol (8.5 µg/g) for 28 days. Values represent means + SD (*p<0.05).

Figure 2.  Effect of (8-hydroxymethylen)-trieicosanyl acetate on the number of amastigote nests observed in BALB/c mice infected with T. cruzi and treated at doses of 2.11, 8.4, and 33.6 µg/g (**p<0.05).

Figure 2.  Effect of (8-hydroxymethylen)-trieicosanyl acetate on the number of amastigote nests observed in BALB/c mice infected with T. cruzi and treated at doses of 2.11, 8.4, and 33.6 µg/g (**p<0.05).

Figure 3. Effect of (8-hydroxymethylen)-trieicosanyl acetate on the mortality rate of BALB/c mice after 28 days of infection with T. cruzi and treated at doses of 2.11, 8.4, and 33.6 µg/g (* p<0.05).

Figure 3.  Effect of (8-hydroxymethylen)-trieicosanyl acetate on the mortality rate of BALB/c mice after 28 days of infection with T. cruzi and treated at doses of 2.11, 8.4, and 33.6 µg/g (* p<0.05).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.